Belgium's UCB sees 1st-qtr sales up 15%

24 April 2017

Belgium’s largest pharma company UCB (Euronext Brussels: UCB) this morning reported that revenue for the first three months of 2017 increased to 1.12 billion euros ($1.22 billion, a rise of 15% at actual and 14% at constant exchange rates (CER).

This was supported by the one-time other revenue of 56 million euros recognized in February 2017 for out-licensing of the OTC-allergy drug Xyzal (levocetirizine).

The company did not provide earnings figures. However, UCB’s shares were down 3.16% at 69.32 euros in mid-morning trading today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK